Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 16/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479881 | 1.00 | CMA1 (0.60) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL10297461 | 1.00 | CMA1 (0.60) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL10297457 | 0.97 | CMA1 (0.62) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL10297434 | 0.97 | CMA1 (0.62) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL14479878 | 0.97 | CMA1 (0.62) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL10297421 | 0.97 | CMA1 (0.62) | CMA1ACEF2PRSS1CTRC | |
| SCHEMBL14479875 | 0.86 | OPRM1 (0.53) | ACEXIAP | |
| SCHEMBL10297462 | 0.86 | OPRM1 (0.53) | ACEXIAP | |
| SCHEMBL10297418 | 0.86 | OPRM1 (0.53) | ACEXIAP | |
| SCHEMBL14479877 | 0.85 | REN (0.53) | CMA1ACEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9114104-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130004941-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2013-01-03 | — | — | US | disclosed |
| US-8211637-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004941-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | CMA1 84/4885ACE 226/4885F2 977/4885 |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | CMA1 84/4885ACE 226/4885F2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.